Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

opdivo_1_1

NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

February 12, 2021
Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …

News

NICE recommends treatments for pregnancy sickness in new draft guidance

February 11, 2021
NICE, Pregnant

NICE has recommended treatment options for severe pregnancy sickness for the first time, issuing recommendations in draft guidance published today.

News

NICE rejects multiple sclerosis drug Zeposia

January 22, 2021
Medical Communications NICE

NICE has decided not to recommend Bristol Myers Squibb’s Zeposia (ozanimod) for the treatment of relapsing/remitting multiple sclerosis (RRMS). In …

News
gilead-sciences

NICE recommends rheumatoid arthritis drug Jyseleca for NHS use

January 21, 2021
Gilead, NICE

NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …

News

NICE approves lipid disorder drug Myalepta for NHS use

January 20, 2021
Research and Development Amryt Pharma, NICE

NICE has approved Amryt’s rare lipid disorder drug Myalepta (metreleptin), currently the only leptin replacement therapy available, for use within …

News

NICE recommends cutting-edge lymphoma treatment for NHS use

January 19, 2021
Manufacturing and Production Cancer, NICE

NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …

News

NICE recommends GSK’s ZEJULA for advanced ovarian cancer

January 15, 2021
Medical Communications Cancer, GlaxoSmithKline, NICE

NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade …

News

NICE recommends AstraZeneca’s FORXIGA for heart failure

January 7, 2021
AstraZeneca, NICE

NICE has issued a positive Final Appraisal Document (FAD) recommending AstraZeneca’s FORXIGA (dapagliflozin) as an option for treatment of symptomatic …

News

Shionogi’s novel antibiotic selected for UK pilot subscription reimbursement model

December 21, 2020
Sales and Marketing NICE, Shionogi, antibiotic

Japanese pharmaceutical company Shionogi today announced that NICE and NHS England and Improvement (NHSE&I) have selected its novel antibiotic Fetcroja …

News

NICE recommends GSK’s Nucala for more asthma patients

December 18, 2020
Medical Communications GlaxoSmithKline, NICE, asthma, mepolizumab

NICE has today published final draft guidance recommending GlaxoSmithKline’s Nucala (mepolizumab) as an add-on treatment option for severe refractory eosinophilic …

News
nice_new_london_office_internal_3_web

NICE recommends Novartis’ Beovu for wet age-related macular degeneration

December 16, 2020
Research and Development NICE, Novartis, wet AMD Beovu

NICE has published its final appraisal of Novartis’ Beovu (brolucizumab), recommending that the drug be made available via the NHS …

News

NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine

December 11, 2020
Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine

NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …

News

NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer

December 10, 2020
Sales and Marketing ALK-positive advanced non-small cell lung cancer, Alunbrig, NICE, Takeda

NICE has published its final appraisal of Takeda’s Alunbrig (brigatinib), recommending the therapy for the treatment of ALK-positive advanced non-small …

News
astrazeneca_sign_sky

NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

December 8, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …

News
lilly_building_with_american_flag_web

NICE recommends Lilly’s Emgality for chronic and episodic migraine

November 18, 2020
Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK

Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026